Halozyme Therapeutics (HALO) Return on Capital Employed (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Return on Capital Employed of 22.9% for Q1 2026, down 728.0% year-over-year from 3.65% in Q1 2025, and up 7.23% quarter-over-quarter from 21.36% in Q4 2025.
Halozyme Therapeutics (HALO) Return on Capital Employed (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Return on Capital Employed for 16 consecutive years, with 22.9% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 728.0% year-over-year to 22.9%; the TTM figure through Mar 2026 stood at 22.9% (down 728.0% YoY), while the FY2025 annual figure was 22.15%, down 920.0% from the prior year.
- Return on Capital Employed climbed to 22.9% in Q1 2026 per HALO's latest filing, from 21.36% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 56.71% in Q3 2025 and bottomed at 14.56% in Q3 2022.
- Historically, Return on Capital Employed has averaged 24.33% across 5 years, with a median of 22.69% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 1536 bps — and 2025, when it soared 3206 bps.
- Halozyme Therapeutics' Return on Capital Employed stood at 15.53% in 2022, then advanced by 28 bps to 19.85% in 2023, then surged by 42 bps to 28.26% in 2024, then declined by 24 bps to 21.36% in 2025, then increased by 7 bps to 22.9% in 2026.
- Business Quant data shows HALO's Return on Capital Employed at 22.9% in Q1 2026, 21.36% in Q4 2025, and 56.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 26.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.19% |
| Mar 31, 2026 | 22.90% |
| Dec 31, 2025 | 21.36% |
| Sep 30, 2025 | 56.71% |
| Jun 30, 2025 | 34.29% |
| Mar 31, 2025 | 30.18% |
| Dec 31, 2024 | 28.26% |
| Sep 30, 2024 | 24.65% |
| Jun 30, 2024 | 22.69% |
| Mar 31, 2024 | 22.91% |
| Dec 31, 2023 | 19.85% |
| Sep 30, 2023 | 17.91% |
| Jun 30, 2023 | 18.68% |
| Mar 31, 2023 | 14.64% |
| Dec 31, 2022 | 15.53% |
| Sep 30, 2022 | 14.56% |
| Jun 30, 2022 | 19.01% |
| Mar 31, 2022 | 29.45% |
| Dec 31, 2021 | 26.84% |
| Sep 30, 2021 | 29.92% |